The case began innocuously. The patient developed persistent hoarseness after an upper respiratory infection, and flexible laryngoscopy revealed a tumor arising from the left true vocal fold and extending toward the anterior commissure. Scans showed the mass confined to the glottic and supraglottic regions of the larynx, with no lymph node involvement or spread to distant organs. A biopsy was read as poorly differentiated squamous cell carcinoma, the most common and most familiar cancer of the head and neck. Because the histology looked conventional, and because the patient was initially staged with a potentially curable stage II disease, no test for NUT carcinoma was performed at that time. That decision, the report makes clear, would shape everything that followed.

Given his youth, the clinical team pursued a larynx-preserving strategy. He received induction chemotherapy with docetaxel, cisplatin, and cetuximab, followed by definitive chemoradiotherapy delivering seventy gray of intensity-modulated radiation with concurrent carboplatin and 5-fluorouracil. The primary tumor vanished completely on endoscopy and imaging, and maintenance therapy with the oral agent S-1 followed. For ten months the remission held. Then, in August 20X1, a recurrent lesion appeared at the original site, this time with paralysis of the vocal fold on the same side. Surgeons performed a total laryngectomy, removing the entire voice box, and pathology again showed moderately to poorly differentiated squamous cell carcinoma. The tumor, everyone assumed, had been dealt with.

It had not. Five months after surgery the patient developed painful swallowing, and imaging revealed an ulcerative mass on the posterior pharyngeal wall along with a solitary lesion in the iliac bone of the pelvis. Chemotherapy with cisplatin and docetaxel failed within a single cycle. The immune checkpoint inhibitor nivolumab, which works well in a subset of head and neck cancers, also failed within weeks. Comprehensive genomic profiling using the FoundationOne CDx assay detected no actionable alterations and, crucially, did not detect the BRD4::NUTM1 fusion—a false negative that is well documented for NUTM1 rearrangements, since DNA-based sequencing depends on where the breakpoint falls and how well that region is captured. The tumor’s biomarker profile, with a low tumor mutational burden of four mutations per megabase and a microsatellite-stable genome, offered no foothold for immunotherapy.

The definitive answer came only after a third salvage operation. Radical surgery at Aichi Cancer Center involved circumferential pharyngectomy, removal of the cervical esophagus, and reconstruction with a free segment of jejunum. When yet another recurrence appeared around the permanent tracheostoma five months later, additional immunohistochemistry on the resected tissue revealed diffuse nuclear staining for the NUT protein with a characteristic speckled pattern, alongside expression of the squamous markers p63 and p40. That single stain established the true diagnosis: NUT carcinoma. Retrospective testing of archived specimens using fluorescence in situ hybridization and RNA-based reverse transcription polymerase chain reaction confirmed a BRD4::NUTM1 fusion and proved the tumor had been NUT carcinoma from the very beginning, hidden behind a costume of ordinary squamous cancer.

The biology explains both the disguise and the ferocity. NUT carcinoma is driven by fusion proteins that typically join the tandem bromodomains of BRD4, which latch onto acetylated histones, to the NUT moiety, which recruits the p300/CBP acetyltransferases. The result is enormous hyperacetylated chromatin domains that force MYC expression and lock immature epithelial cells into a perpetual, proliferating, non-differentiating state. Because the cells still express squamous markers such as p63 and p40, pathologists see a plausible squamous cell carcinoma under the microscope. Only diffuse NUT immunostaining or molecular detection of the NUTM1 rearrangement separates the two diseases, and the report argues forcefully that young, non-smoking patients with aggressive, poorly differentiated tumors at midline or head and neck sites should trigger NUT-specific testing early.

With the diagnosis finally in hand, the team tried what mechanistic logic suggested should work. A bromodomain and extra-terminal, or BET, inhibitor—the class of drugs designed precisely to displace BRD4 from acetylated chromatin—was given through a clinical trial. The response was swift and dramatic: imaging at three months showed a marked partial regression. But after roughly six months, new lesions emerged and treatment stopped after eight cycles. Resistance to BET inhibition is thought to arise not through target mutations but through adaptive rewiring, in which tumor cells restore MYC-centered transcriptional programs using compensatory co-regulators such as p300/CBP and histone deacetylases, or bypass signaling through the MAPK/ERK pathway. A trial of the histone deacetylase inhibitor vorinostat, intended to attack that same acetylation circuitry from the opposite direction, produced no control whatsoever, consistent with functional redundancy between HDAC1 and HDAC2.

Even intensive cytotoxic chemotherapy delivered only borrowed time. Alternating cycles of vincristine, doxorubicin, and cyclophosphamide with ifosfamide and etoposide—a regimen borrowed from pediatric sarcoma practice—shrank the tumor markedly after two cycles, a reminder that this highly proliferative cancer retains some sensitivity to DNA-damaging agents. Yet regrowth appeared during the third cycle. Paclitaxel with cetuximab failed twice, and pembrolizumab combined with cisplatin and 5-fluorouracil achieved nothing. By June 20X4 the disease had replaced much of the anterior neck, and care shifted to palliation. Weekly applications of Mohs paste, a zinc chloride-based preparation rarely discussed in modern oncology, were used to harden the tumor surface and control malodorous exudate and bleeding, while morphine managed pain. The patient died in late July with his family present, having lost more than thirty kilograms from his baseline weight.

The autopsy delivered the report’s most consequential insight. Although the lungs were studded with innumerable metastatic nodules, each only a few millimeters across, the immediate cause of death was not disseminated cancer. It was overwhelming infection driven by uncontrolled locoregional disease—a massive twenty-three by twenty centimeter infiltrative tumor occupying the neck, invading the reconstructed jejunum, and compromising the airway, complicated by bilateral cavitary lung abscesses. This distribution matters therapeutically: fatal outcomes in NUT carcinoma may hinge less on distant metastasis than on relentless local progression along the aerodigestive tract, reinforcing evidence from prior series that durable locoregional control with surgery and radiotherapy underpins the only long-term survivals recorded.

The authors place their experience against the eighteen previously documented laryngeal cases, most of which arose in the supraglottis and claimed their victims within a year. Their patient’s glottic origin, four-year course, and autopsy characterization are all firsts for this site, and his survival of more than two years beyond the detection of an iliac bone metastasis stands against registry data showing zero percent two-year survival for metastatic head and neck NUT carcinoma. The broader lesson is uncomfortable but clear: despite its microscopic resemblance to squamous cell carcinoma, this is a transcription-addicted malignancy that standard head and neck regimens—induction chemotherapy, platinum-taxane combinations, and checkpoint inhibitors—all failed to hold in check. Some researchers now argue NUT carcinoma should be regarded as a molecularly defined subtype of squamous carcinoma rather than a separate entity, a framing that would push NUT testing into routine practice. Whether future patients benefit will likely depend on diagnosing the fusion early and combining epigenetic drugs with cytotoxic debulking and definitive local therapy, rather than adding agents one at a time to a network evolution too easily circumvents.

Subject of Research: Diagnosis and treatment resistance in BRD4::NUTM1 fusion laryngeal NUT carcinoma

Article Title: Laryngeal NUT Carcinoma With BRD4::NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy

Article References: Kanno, M., Sasaki, C., Kato, E., Terada, H., Hanai, N., Sasaki, E., Fukushima, M., Masuishi, T., Takanari, K., Fukada, Y., Miyazaki, Y., Sonoda, Y., Kato, Y., Morikawa, T., Takabayashi, T., & Fujieda, S. (2026). Laryngeal NUT Carcinoma With BRD4 :: NUTM1 Fusion: A 4‐Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy. Cancer Reports, 9(9), Article e70679. https://doi.org/10.1002/cnr2.70679

Image Credits: AI Generated

DOI: 10.1002/cnr2.70679

Keywords: NUT carcinoma, BRD4::NUTM1 fusion, laryngeal cancer, BET inhibitor, vorinostat, squamous cell carcinoma, NUTM1 rearrangement, chemoradiotherapy, immune checkpoint inhibitor, autopsy findings, epigenetic therapy, rare cancer

The strategy grew out of a long-standing interest in cellular senescence, a stress response that permanently halts cell division. Senescent cells are famously double-edged. When a cell accumulates dangerous damage, senescence shuts it down before it can become cancerous, and during wound healing, senescent cells coordinate repair by broadcasting signals that recruit other cells to the injury site. The trouble begins when these cells overstay their welcome. Instead of quietly disappearing once their job is done, lingering senescent cells keep emitting inflammatory and profibrotic signals that drive chronic inflammation and scarring. Scott Lowe, who chairs the Cancer Biology and Genetics Program at MSK’s Sloan Kettering Institute and is a Howard Hughes Medical Institute investigator, has spent years probing this duality. The therapeutic dream, he explains, is to clear the harmful senescent cells while sparing the helpful ones—a goal that has proven difficult because senescent cells in different contexts can look deceptively similar.

The breakthrough came when the researchers examined macrophages, the scavenger immune cells that patrol tissues, in fibrotic environments. Within these populations, they identified a small subset expressing a surface protein called P-selectin alongside multiple molecular hallmarks of senescence. The team dubbed these cells MΦP+sen+—macrophages that are both P-selectin positive and senescence positive. What struck the scientists was their consistency: the same distinctive population appeared in fibrotic tumor niches in liver and lung cancers and in heavily scarred liver and lung tissue, and its presence correlated with poorer responses to immunotherapy in patients. Clemens Hinterleitner, a postdoctoral researcher and co-first author of the study, notes that finding this specific macrophage population so reliably in fibrotic tissue was remarkable, and that its presence signaled a compromised local immune environment.

These cells are far more than innocent bystanders. According to the study, MΦP+sen+ macrophages contribute to the fibrosis that forms a physical barrier around tumors, and they simultaneously dampen the activity of neighboring immune cells by sending out profibrotic and immunosuppressive signals. Co-first author Valentin Barthet describes them as actively erecting a wall that prevents the immune system from doing its job. The cells make up only about 3 to 5 percent of fibrotic tissue, yet experiments in mouse models of liver and lung fibrosis and fibrotic liver and lung cancers showed that selectively killing them or silencing their signals had a profound effect on fibrosis. The team validated the key findings in tumor samples from lung cancer patients treated at MSK and in human lung and liver cancer datasets, lending clinical weight to the mouse data.

The consequences of eliminating or disabling these macrophages were dramatic. The scar tissue shielding the tumor began to dissolve, and the suppression of other immune cells eased. Freed from both the physical and chemical barriers, checkpoint inhibitor immunotherapy—the class of drugs that unleashes T cells against cancer—suddenly worked in mice, shrinking tumors that had previously been resistant to treatment. In other words, the intervention did not attack the cancer cells directly. It removed the ecosystem support that allowed the tumor to hide, converting a cold, immune-excluded tumor microenvironment into one that existing therapies could penetrate.

Delivering a lethal payload to such a small and specific cell population posed a formidable engineering challenge, and this is where the collaboration with Daniel Heller’s biomedical engineering lab proved decisive. Heller’s group had previously developed a nanoparticle platform that targets P-selectin, and the team adapted it with new drugs and a new mission. The particles are roughly a thousand times smaller than the width of a human hair and are coated with fucoidan, a naturally occurring sugar molecule found in brown seaweed and sold as an anti-inflammatory supplement. Fucoidan binds specifically to P-selectin, ensuring that the nanoparticles are taken up not by just any macrophage but by the precise P-selectin-positive subset driving the fibrosis. When the targeted macrophages ingest and digest a particle, the drug inside is released—an effect Heller likens to soldiers springing from a Trojan Horse to launch a precision attack from within.

The researchers loaded the nanoparticles with two drugs that are potent against senescent cells but have been hampered by toxicity in clinical use. The first, Navitoclax, exploits a vulnerability in senescent cells’ survival machinery: these stressed cells block their own natural self-destruct program, and Navitoclax removes that block, causing them to die. The second, a BET inhibitor called dBET6, takes a different tack—it silences the inflammatory signals that senescent cells broadcast into surrounding tissue. With the alarm switched off, the cells stop producing the signals that drive fibrosis and immune suppression, even though the cells themselves survive. Both drugs had shown promise against cellular senescence in the laboratory but failed clinically because, when administered conventionally, they damage healthy cells and tissues throughout the body. In the mouse experiments, the nanoparticle-packaged versions appeared safe and did not produce the same toxicity, raising the possibility that targeted delivery could give both drugs a second chance in the clinic.

The implications may extend well beyond liver and lung cancer. Searching a large database of immune cell profiles, the researchers found the same harmful macrophage population associated with breast and colon cancers as well as chronic inflammatory diseases including osteoarthritis and rheumatoid arthritis. Aveline Filliol, a senior scientist in the Lowe Lab and co-corresponding author, points out that these macrophages also share important features with lipid-associated macrophages, a cell type found in the atherosclerotic plaques that cause heart disease—suggesting the platform could one day be adapted to deliver drugs to those cells as well. If MΦP+sen+ cells prove to be a common culprit across many diseases, a single nanoparticle platform, retargeted with different drug cargoes, could address an unusually wide range of conditions united by a shared cellular mechanism.

Beyond the specific findings, the work exemplifies an increasingly influential strategy in oncology: targeting the cancer ecosystem rather than the tumor cells alone. Cancer cells, Lowe argues, do not act in isolation; building a tumor-supportive environment requires coordinated interactions between malignant cells and the surrounding tissue, and disrupting those interactions represents a significant new frontier. The study also showcases the kind of interdisciplinary collaboration—between biologists and engineers, and between bench scientists and clinicians—that allowed the team to move from a biological observation to an engineering solution to validation in human tissue within a single institution. MSK is now seeking commercialization partners to advance the research into clinical trials, first in cancer and potentially in other fibrotic and inflammatory diseases. A patent application covering the use of fucoidan nanoparticles to treat senescence-associated pathologies has been published, and related intellectual property has been granted, signaling that the road from laboratory insight to patient benefit is already under construction. If the approach survives the rigors of human testing, it could offer a way to make immunotherapy work for the many patients it currently fails—and to treat the scarred, inflamed tissue that underlies diseases far beyond cancer.

Subject of Research: Senescence-directed nanoparticle targeting of fibrosis-driving macrophages to overcome immune exclusion in cancer

Article Title: Using nanoparticles to target fibrosis in cancer and other diseases

Article References: Using nanoparticles to target fibrosis in cancer and other diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nanoparticles, fibrosis, cellular senescence, macrophages, immunotherapy, cancer, P-selectin, fucoidan, Navitoclax, BET inhibitor, tumor microenvironment, checkpoint inhibitors